Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H34ClN2O8PS |
Molecular Weight | 504.963 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O
InChI
InChIKey=UFUVLHLTWXBHGZ-MGZQPHGTSA-N
InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1
Molecular Formula | C18H34ClN2O8PS |
Molecular Weight | 504.963 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfCurator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf
Curator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as some Gram-negative anaerobes.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9797245http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105985/pdf/ac003014.pdf
Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin
with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123 |
|||
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN T Approved UseClindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date1980 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseLower respiratory tract infections including pneumonia, empyema, and lung abscess
caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis),
and Staphylococcus aureus. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSkin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus
aureus, and anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseGynecological infections including endometritis, nongonococcal tubo-ovarian abscess,
pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseIntra-abdominal infections including peritonitis and intra-abdominal abscess caused by
susceptible anaerobic organisms. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSepticemia caused by Staphylococcus aureus, streptococci (except Enterococcus
faecalis), and susceptible anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseBone and joint infections including acute hematogenous osteomyelitis caused by
Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic
bone and joint infections due to susceptible organisms. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.92 ng/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.54 ng × h/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: |
unhealthy, 16 - 51 |
Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vaginal pain or burning | 1.2% Disc. AE |
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: |
unhealthy, 16 - 51 |
Anaphylactic shock | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypersensitivity reaction | severe Disc. AE |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Toxic epidermal necrolysis | grade 3-5 Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Reaction skin | severe Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0 |
moderate [Inhibition 100 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
minor | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined |
PubMed
Title | Date | PubMed |
---|---|---|
Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris. | 2001 Feb |
|
Anti-anaerobic activity of antibacterial agents. | 2001 Feb |
|
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. | 2001 Feb |
|
Two cases of diskitis attributable to anaerobic bacteria in children. | 2001 Feb |
|
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. | 2001 Feb |
|
Folliculitis decalvans. | 2001 Jan |
|
Emerging erythromycin resistance among group B streptococci in Korea. | 2001 Jan |
|
Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. | 2001 Jan |
|
Puerperal sepsis: a disease of the past? | 2001 Jan |
|
Clostridium difficile colitis following antibiotic prophylaxis for dental procedures. | 2001 Jan |
|
Babesiosis. | 2001 Jan |
|
Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-center experience. | 2001 Jan |
|
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998). | 2001 Jan 1 |
|
[The therapeutic approach to necrotizing fasciitis]. | 2001 Mar |
|
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis]. | 2001 Mar |
|
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. | 2001 Mar |
|
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998. | 2001 Mar |
|
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. | 2001 Mar |
|
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. | 2001 Mar |
|
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. | 2001 Mar 30 |
|
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women? | 2001 May |
|
Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. | 2001 May-Jun |
|
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. | 2001 Spring |
|
Erythromycin and amoxicillin? | 2001 Winter |
|
Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis. | 2015 |
Sample Use Guides
Intravenous and Intramuscular: 600-1200 mg/day in 2,3 or 4 equal doses; for the more severe infections: 1200-2700 mg/day in 2,3 or equal doses. Doses of as much as 4800 mg daily have been given intravenously. Single intramuscular injection of greater than 600 mg not recommended.
Topical: apply a thin film of solution, lotion or gel twice daily to affected area.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/634877
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
The minimal inhibitory concentration (MIC) for clindamycin against Staph. Aureus is 0.5 ug/ml with 97% of strains inhibited at this level. For anaerobes, the MIC is 1.6 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:09 GMT 2025
by
admin
on
Mon Mar 31 17:54:09 GMT 2025
|
Record UNII |
EH6D7113I8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C82922
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
797272
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID1048677
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
246-433-0
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
443385
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
EH6D7113I8
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
DUAC
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | APPROVED MARCH 2015 | ||
|
CHEMBL3184512
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
1138008
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
24729-96-2
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
618653
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
100000090555
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
EH6D7113I8
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
SUB01344MIG
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
C47978
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
DBSALT000778
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
m3624
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
CLINDAMYCIN PHOSPHATE
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder.Solubility: Freely soluble in water; very slightly soluble in ethanol (~750 g/l) TS and acetone R.Category: Antibacterial drug.Storage: Clindamycin phosphate should be kept in a tightly closed container.Labelling: The designation Clindamycin phosphate for parenteral use indicates that the substance complies with the additionalrequirements and may be used for parenteral administration. Expiry date.Additional information: Clindamycin phosphate is slightly hygroscopic. | ||
|
3909
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|